Add to favorites

#Industry News

CARMAT RESUMES ARTIFICIAL HEART TRIALS

French Company Receives Recruitment Go-Ahead

Yesterday, Carmat announced it is to resume trials for its prosthetic heart. The French based company manufactures the world’s most sophisticated complete artificial heart. It recently received approval from the comité de protection des personnes (ethics committee) among other french regulatory bodies to begin recruiting new patients to its trial program.

Following the death of the first implant patient, Claude Dany, 76, Carmat reiterated its commitment to maintain its existing program comprising four patients. However, patient recruitment was put on hold to give Carmat the opportunity to analyze the data from the first implanted prosthesis. With approval now secure, the company will look to recruit three more patients to its ongoing clinical trial program.

This should bring hope to the tens of thousand of people who are on heart-transplant waiting lists. Carmat’s artificial heart is designed to last five years, but the company would deem anything over one month of patient survival a success.

Details

  • France
  • Carmat